Passage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights
May 11, 2020 07:00 ET
|
Passage Bio
– Expansion of gene therapy collaboration with University of Pennsylvania’s Gene Therapy Program extends collaboration by three additional years and adds five new programs – – Orphan Drug...
Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania
May 07, 2020 07:30 ET
|
Passage Bio
Option to license an additional five programs for a total of seventeenExtended option and research term to allow for collaboration through 2025Exclusive rights to certain technologies resulting from...
Passage Bio to Report First Quarter 2020 Financial Results on May 11, 2020
May 04, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, May 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system...
FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis
April 21, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, April 21, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio to Present at 19th Annual Needham Healthcare Conference
April 08, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, April 08, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
March 27, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, March 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares
March 09, 2020 16:30 ET
|
Passage Bio
PHILADELPHIA, March 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Appoints Athena Countouriotis to Board of Directors
March 05, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, March 05, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Announces Pricing of Initial Public Offering
February 27, 2020 19:24 ET
|
Passage Bio
PHILADELPHIA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders...
Passage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive Officer
January 28, 2020 08:00 ET
|
Passage Bio
PHILADELPHIA, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with...